An experimental Parkinson’s vaccine was generally safe and triggered an immune response against aggregated alpha-synuclein in ...
The FDA has approved Juvmo, an oral tavapadon treatment for adults with Parkinson’s disease, following three pivotal phase 3 ...
AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved JUVMO™ (tavapadon) tablets as the first ...
AbbVie (ABBV) wins FDA approval for Juvmo, a first-in-class Parkinson's disease treatment targeting D1/D5 receptors, ...
AbbVie (ABBV) gains FDA approval for Juvmo, a first-in-class Parkinson's treatment launching October 2026. Stock dips 0.29% despite breakthrough.
AbbVie (ABBV) gains FDA approval for Juvmo, a novel Parkinson's drug using unique D1/D5 receptor targeting. U.S. launch set ...
AbbVie stock (ABBV) slipped slightly on Monday, down 0.29%, after the company announced a major regulatory win. The FDA ...
When it comes to Parkinson's disease, we inevitably focus on "movement," such as tremors, freezing of gait, and rigidity.But ...
AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved JUVMO (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for the treatment of adults with ...
The FDA has approved Juvmo, the first and only dopamine agonist for adults with Parkinson’s disease designed to selectively ...
The FDA approved the dopamine agonist tavapadon (Juvmo) to treat adults with Parkinson's disease, drugmaker AbbVie announced ...
AC Immune (NASDAQ:ACIU) reported results from Part 1 of its VacSYn Phase II trial evaluating ACI-7104.056, an active ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results